NME Slump Continues: FDA Clears 18 Novel Drugs In 2006, Same As 2005
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA's final approval tally of new molecular entities in 2006 is almost a 25-year low, despite early signs that the agency was on pace to best last year's final count of NME approvals
You may also be interested in...
FDA First-Cycle Approval Rate Is Silver Lining In Cloud Of Low NME Count
Three-quarters of the new molecular entities cleared by FDA in 2007 were approved on the first review cycle, a high for this decade and a positive note to counterbalance the record low number of NMEs approved
FDA First-Cycle Approval Rate Is Silver Lining In Cloud Of Low NME Count
Three-quarters of the new molecular entities cleared by FDA in 2007 were approved on the first review cycle, a high for this decade and a positive note to counterbalance the record low number of NMEs approved
End Of Phase II Meetings Used By Less Than Half The Firms In PwC Survey
Fewer than half of drug companies participating in a PricewaterhouseCoopers survey participated in a meeting with FDA at the conclusion of Phase II studies